Agentix Corp. (AGTX)
Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Agentix Corp.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 40.07M shares outstanding
USAgentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders.
Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases.
The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019.
Its operations are based in Dana Point, California.
Leadership
David Fiene
Financial Controller
Martin Schroeder
Chief Scientific Officer & Member of Scientific Advisory Board
Riazul Huda
Chief Executive Officer, Chief Financial Officer & Director
Employees
3
Country
US
Sector
Healthcare
Website
agentixcorp.com
based on 40.07M shares outstanding
US30d Avg
185.15K
60d Avg
185.15K
90d Avg
119.71K